Biopharma merger and acquisition activity in 2020 was mainly filled with late-stage- bolt-on acquisitions- which were orders of magnitude smaller than the mega M&A deals of prior years.AstraZeneca holds the top rank by acquiring Alexion Pharmaceuticals among the top 20 acquisitions with a total deal value of $39B at a 1-day premium of 45%…
